Empagliflozina e Glicogenose tipo Ib

Referências

1. Grünert, S. C., Derks, T. G. J., Mundy, H., Dalton, R. N., Donadieu, J., Hofbauer, P., Jones, N., Uçar, S. K., LaFreniere, J., Contreras, E. L., Pendyal, S., Rossi, A., Schneider, B., Spiegel, R., Stepien, K. M., Wesol-Kucharska, D., Veiga-da-Cunha, M., & Wortmann, S. B. (2024). Treatment recommendations for glycogen storage disease type IB- associated neutropenia and neutrophil dysfunction with empagliflozin: Consensus from an international workshop. In Molecular Genetics and Metabolism (Vol. 141, Issue 3, p. 108144). Elsevier BV. https://doi.org/10.1016/j.ymgme.2024.108144 

2. Li, Z., Zhang, X., Chen, H., Zeng, H., Wu, J., Wang, Y., Ma, N., Lan, J., Zhang, Y., Niu, H., Shang, L., Jiang, X., & Yang, M. (2024). Empagliflozin in children with glycogen storage disease-associated inflammatory bowel disease: a prospective, single-arm, open-label clinical trial. In Scientific Reports (Vol. 14, Issue 1). Springer Science and Business Media LLC. https://doi.org/10.1038/s41598-024-59320-z 

3. Veiga-da-Cunha, M., Chevalier, N., Stephenne, X., Defour, J.-P., Paczia, N., Ferster, A., Achouri, Y., Dewulf, J. P., Linster, C. L., Bommer, G. T., & Van Schaftingen, E. (2019). Failure to eliminate a phosphorylated glucose analog leads to neutropenia in patients with G6PT and G6PC3 deficiency. In Proceedings of the National Academy of Sciences (Vol. 116, Issue 4, pp. 1241–1250). Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1816143116 

4. Wortmann, S. B., Van Hove, J. L. K., Derks, T. G. J., Chevalier, N., Knight, V., Koller, A., Oussoren, E., Mayr, J. A., van Spronsen, F. J., Lagler, F. B., Gaughan, S., Van Schaftingen, E., & Veiga-da-Cunha, M. (2020). Treating neutropenia and neutrophil dysfunction in glycogen storage disease type Ib with an SGLT2 inhibitor. In Blood (Vol. 136, Issue 9, pp. 1033–1043). American Society of Hematology. https://doi.org/10.1182/blood.2019004465